Drugs / Albaconazole
Albaconazole
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT01039883 | Nov 2009 → Jan 2010 | tinea unguium | Stiefel, a GSK Company | Completed | No outcome recorded |
| Phase 1 | NCT00509275 | Jul 2007 → Aug 2008 | tinea pedis | Stiefel, a GSK Company | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT00199264 | Jun → Oct 2004 | vulvovaginal candidiasis | J. Uriach and Company | Terminated | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT00730405 Comparator | Jul 2008 → Feb 2010 | tinea unguium | Stiefel, a GSK Company | Completed | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Albaconazole | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00730405 ↗ |
| Known as | Albaconazol | ChEMBL registry synonym — accepted as the source's own label CHEMBL298817 ↗ |
| Known as | UR-9825 | ChEMBL registry synonym — accepted as the source's own label CHEMBL298817 ↗ |
| Known as | W0027 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00509275 ↗ |
| Modality | Small molecule | — CHEMBL298817 ↗ |
| Route | Oral | “as a single oral dose” NCT00199264 ↗ |